48 results about "SOX9" patented technology

Described herein are methods for predicting the recurrence, progression, and metastatic potential of a prostate cancer in a subject. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of FOXO1A, SOX9, CLNS1A, PTGDS, XPO1, LETMD1, RAD23B, ABCC3, APC, CHES1, EDNRA, FRZB, HSPG2, and TMPRSS2_ETV1 FUSION. The method can further comprise detecting in a sample from a subject one or more biomarkers selected from the group consisting of miR-103, miR-339, miR-183, miR-182, miR-136, and miR-221. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer.

A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFR[alpha]+KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGF[beta] inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFR[beta]+ paraxial mesoderm population with a TGF[beta]3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.

The invention relates to a colorectal cancer metabolic gene prognosis prediction model, relates to biomarkers UGT2A, ACAA2, PKM, GPX3, PAFAH1B3 and SOX9, and further comprises application of reagents for detecting the expression quantity of the markers in preparation of a kit for evaluating colorectal cancer prognosis survival. The prognosis of a patient is judged on the basis of the diagnostic markers and a corresponding prediction model (i.e., according to the sum of products of expression quantities and coefficients of six metabolism-related genes and clinical characteristics of the patient are combined), which have the advantage of efficiently and accurately predicting the prognosis of the colorectal cancer patient, effective guidance is provided for clinicians to make a treatment decision on the colorectal cancer patient, invalid treatment is reduced, and therefore the treatment cost and uncomfortable experience of the patient are reduced.

The invention relates to a cynoglossus semilaevis female specificity CSW3 protein as well as a gene and an application thereof, which belong to the technical field of functional gene selection and application in an aquatic biological technology. The amino acid sequence of the cynoglossus semilaevis female specificity CSW3 protein is SEQ ID NO. 1; a nucleotide sequence for encoding the CSW3 gene of the CSW3 protein is SEQ ID NO.2. By adopting the in-vitro recombination cynoglossus semilaevis female specificity CSW3 protein of the CSW3 gene, the expression level of female relevant gene foxl2 can be obviously increased, and the biological activity for stimulating the female relevant gene expression can be realized; meanwhile, the biological activity for reducing the male relevant gene sox9 and amh expression level can be realized. After a CSW3 gene recombination product is used as a feed additive, the development of the female gonad can be stimulated, and the ratio of the female fish can be increased, so that the cynoglossus semilaevis female specificity CSW3 protein has the application potential on controlling the gender of the cynoglossus semilaevis and increasing the ratio of the female fish fries.

The invention discloses a culture method for inducing chondrogenic differentiation of adipose-derived stem cells and a culture solution. The culture method comprises the following steps: (1) taking asubcutaneous fatty tissue, washing the subcutaneous fatty tissue, removing an adipose tissue membrane and blood vessels and shearing the subcutaneous fatty tissue into broken blocks, carrying out enzymic digestion, adding a complete medium, centrifuging to remove adipose cells and lipid droplets, resuspending on the complete medium, inoculating into a culture bottle, culturing for 24 h and then changing the culture solution to remove cells which are not attached to walls, changing the solution every three days, digesting for 3-5 min with 0.25% of pancreatin and 1 mmol/L EDTA at the temperatureof 37 DEG C after cell fusion, stopping digestion of the complete medium, and carrying out passage at the ratio of 1: 2; and (2) inoculating passage cells into the culture bottle which contains the complete medium, culturing for 48h and then changing the medium into an incomplete medium, adding a Sox9 gene activator to continue culturing, and changing the medium every three days. By the providedmethod, chondrogenic differentiation of the adipose-derived stem cells can be induced effectively, the adipose-derived stem cells can be used as seed cells to prepare a large number of chondrocytes tomeet clinic requirements to the chondrocytes.

The invention relates to an N-gallic amide-pyrimidine phenyl sulfonamide compound as well as a preparation method and an application of the compound in preparation of medicines for resisting bacteria and promoting the growth of cartilage cells. The N-gallic amide-pyrimidine phenyl sulfonamide compound and a water soluble salt thereof have certain bacteriostatic action on staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, acinetobacter, proteusbacillus vulgaris, pulmonary tuberculosis and the like in vitro, and have an obvious promotion effect on proliferation of bone cells, and synthesis of total protein and glycosaminoglycan in chondrocyte, the gene levels of proteoglycan, II collagen and SOX9 gene can also be regulated upwards, the gene level of I collagen can be inhibited, secretion and synthesis of extracellular matrix of the cartilage can be promoted, and the compound can be applied to preparation of the medicines for treating osteoarthritis.

The invention relates to a female cynoglossus semilaevis specific protein CSW2, whose amino acid sequence is represented by the SEQ ID No.2; the sequence of the nucleotide, which encodes the female cynoglossus semilaevis specific protein CSW2, is represented by the SEQ ID No.1. The external recombinant protein of the CSW2 gene can prominently improve the aromatizing enzyme expression level of female cynoglossus semilaevis fry related genes, namely fox12 and P450, has a biological activity which can promote female-related gene expression, and at the same time has a biological activity that can reduce the expression level of male-related gene SOX9. The recombinant expression product of CSW2 can be used as a feed addictive, which has the function of promoting the growth of female gonad and has an effect of improving the female fish ratio. So the CSW2 gene provided by the invention has a potential application prospect on aspects of cynoglossus semilaevis gender control and improvement on the female fry ratio.

Disclosed is a cell which enables the reproduction of a cartilage tissue and has a proliferative ability. Also disclosed is a technique for providing a cell supply source which can be used in a definitive treatment of osteochondrosis deformans. A chondrocyte-like cell which has the same properties as those of a chondrocyte and can proliferate can be produced by selecting a combination of an Myc family gene and/or a Klf family gene and a SOX9 gene and introducing the combination into a somatic cell. The chondrocyte-like cell can be used for a medical purpose of cartilage regeneration.

The invention relates to an application of combination of morroniside and stem cells to preparation of cartilage repair materials. Morroniside can promote phosphorylation of an Smad3 signal channel ofa rat MSC cultured in vitro to improve expression of the Sox9 protein level of the rat MSC without affecting the expression level of endogenous TGF-beta 3 genes of the rat MSC, TGF-beta receptors areinhibited through Ly2157299,, the phosphorylation effect of an SMAD3 signal channel of the rat MSC cultured in vitro is inhibited, and the expression of the Sox9 protein level is reduced. When the morroniside is applied to the rat MSC to which the Ly2157299 is applied, the inhibition effect of the Ly2157299 on the phosphorylation of the SMAD3 can be partially reversed. The etiology acidificationof an ERK signal channel is inhibited through U0126, and the phosphorylation effect of the SMAD3 signal channel of the rat MSC cultured in vitro is inhibited.

The present disclosure concerns at least methods and compositions for repairing and/or regenerating a disc of an individual in need thereof. In certain embodiments, an individual that is known to have or suspected to have or at risk for having a degenerated disc is provided a therapeutically effective amount of nucleus pulposus cells, one or more components from the nucleus pulposus, conditioned medium generated from nucleus pulposus cells, and additionally may also be provided fibroblasts, platelet rich plasma (PRP), SOX9 (protein or nucleic acid), and/or Tie2+ cells, for example.

The invention relates to 3,4,5-trihydroxy gallic acrylamide benzene sulfonamide compounds as well as a preparation method and an application of the compounds in preparation of medicines for resisting bacteria and promoting the growth of cartilage cells. Most of compounds in the compounds have certain bacteriostatic action on staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, acinetobacter, proteusbacillus vulgaris, pulmonary tuberculosis and the like in vitro, and have an obvious promotion effect on proliferation of bone cells, and synthesis of total protein and glycosaminoglycan in chondrocyte, the gene levels of proteoglycan, II collagen and SOX9 gene can also be regulated upwards, the gene level of I collagen can be inhibited, secretion and synthesis of extracellular matrix of the cartilage can be promoted, and the compounds can be applied to preparation of medicines for treating osteoarthritis.

A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided.

The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREBS, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

The invention discloses application of five biomarkers in preparation or screening of a liver cancer diagnostic reagent. The biomarkers comprise at least one of following genes: CD47, Tcf19, Cldn3, Sox4 and Sox9. The five biomarkers can be used for effectively predicting the risk of cancer recurrence of a patient and provide assistance for clinical treatment.